Depuy Hip Lawyer

Aug 26, 2012 by sergiolind32

The Senate Special Committee on Aging held a hearing on April 13th relating to how medical devices are approved for sale by the FDA. The hip replacement recall of the DePuy ASR was also discussed at the hearing, putting emphasis on the significance of the testing and far better post-market place surveillance of medical devices.

The government agency has two processes to approve medical devices: the Premarket Approval Procedure demands clinical trials, while the rapidly-track procedure, the 501(k), only calls for that a product is comparable to other approved products already on the market. The DePuy ASR hip replacement was approved through the 501(k) method, which needed minimal testing of the device. The FDA’s quick-track procedure has come beneath scrutiny since hip implants, which are considered a high-danger device, are cleared by way of the non-rigorous 501(k) process.

The hearing integrated testimony from patient-safety advocates, industry representatives, and an ASR hip implant recipient. The patient disclosed that her doctor had received $600,000 in consulting charges from DePuy Orthopaedics. The quantity, unfortunately, is consistent with the bribery complaint Johnson & Johnson, DePuy’s parent business, recently settled for $70 million. The firm admitted to bribing European doctors and well being-care providers in order to sell their merchandise, including the DePuy hip replacement device.

Mass Device website, which published an write-up relating to the hearing, quoted DePuy’s Director of Communications as stating that the organization supports efforts to boost patient safety, the establishment of a national joint registry in the U.S., and that DePuy would perform “.with the FDA to strengthen an currently-robust method that has worked well for 3 decades and evolved, when appropriate, to much better serve patients.” Thinking about the quantity of recalls of 501(k) approved items, it is troubling that DePuy would call the approach ‘robust,’ specifically because the business had its own item recalled. Though there is pressure from the medical device market to lighten the approval burden, patient safety should not be neglected in order to make funds, only to have the device recalled later. DePuy not only created a faulty device, but also failed to timely warn surgeons and patients of the wellness risks of the device. The hip replacement recall of the ASR, which was implanted in more than 30,000 patients in the U.S., helped shed a light on the value of clinical trials and tougher FDA approval method to make sure patient safety.

Depuy hip lawyers can help those who have suffered from a defective Depuy hip replacement device file a depuy hip lawsuit